Ibogaine for Opioid Use Disorder: An Unrecognized Risk.

Area of Science:

• Addiction Medicine
• Psychopharmacology
• Public Health

Background:

• Growing interest in ibogaine for opioid use disorder (OUD) treatment.
• Policy and public attention are increasing, with state funding for research.
• Some ibogaine advocates position it as an alternative to, rather than a complement to, standard OUD medications.

Purpose of the Study:

• To highlight the potential risks of replacing established, mortality-reducing medications for OUD (MOUD) with unproven therapies like ibogaine.
• To inform the addiction medicine community about the risks associated with ibogaine therapy for OUD.
• To advocate for the continued defense of evidence-based care during the development of novel OUD treatments.

Main Methods:

• Literature review and synthesis of current research on ibogaine and OUD.
• Analysis of the potential risks and benefits of ibogaine compared to MOUD.
• Expert opinion and consensus building within the addiction medicine community.

Main Results:

• Ibogaine is being investigated for OUD, but its efficacy and safety compared to MOUD are not yet fully established.
• Discontinuing MOUD (methadone, buprenorphine) for unproven treatments like ibogaine may elevate the risk of opioid overdose.
• Individual recovery paths vary, underscoring the need for personalized and evidence-based treatment approaches.

Conclusions:

• The addiction medicine community must be vigilant about the potential risks of substituting MOUD with unproven therapies.
• Evidence-based treatments for OUD remain the cornerstone of patient care and mortality reduction.
• Continued research into novel treatments like ibogaine should proceed cautiously, prioritizing patient safety and established therapeutic protocols.